Holen Sie sich die Stockscreener-App
107.05
0.14%
0.145
Vorhandelsmarkt:
106.10
-0.945
-0.88%
Schlusskurs vom Vortag:
$106.90
Offen:
$106.38
24-Stunden-Volumen:
311.07K
Relative Volume:
0.54
Marktkapitalisierung:
$8.31B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-224.29M
KGV:
-27.45
EPS:
-3.9
Netto-Cashflow:
$-185.06M
1W Leistung:
-1.85%
1M Leistung:
+17.61%
6M Leistung:
+39.35%
1J Leistung:
+13.61%
1-Tages-Spanne:
$104.95
$108.04
1-Wochen-Bereich:
$103.51
$109.45
52-Wochen-Spanne:
$55.53
$112.88
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Vergleichen Sie NUVL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
107.05 | 8.30B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-12 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
Russell Investments Group Ltd. Sells 28,747 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Rhumbline Advisers Has $5.04 Million Stock Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Layoff Watch: Is Nuvalent Inc stock trading at a premium valuationEarnings Growth Summary & Free Expert Verified Stock Movement Alerts - BỘ NỘI VỤ
NUVL: Late-stage oncology assets show strong efficacy and safety, with first approvals targeted for 2026 - TradingView
Will Nuvalent Inc. stock attract more institutional investorsMarket Sentiment Summary & Long-Term Safe Investment Ideas - Newser
Nuvalent Insider Sold Shares Worth $434,319, According to a Recent SEC Filing - marketscreener.com
(NUVL) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Returns Recap: Is Nuvalent Inc. stock trading near support levelsJuly 2025 Volume & Long Hold Capital Preservation Tips - BỘ NỘI VỤ
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference - Eastern Progress
Does Nuvalent’s Recent Trial Success Justify the Stock’s 36% 2025 Rally? - Yahoo Finance
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Nuvalent to Participate in the Piper Sandler 37th Annual Healthc - GuruFocus
Nuvalent: Deerfield funds sell $70.8m in NUVL stock By Investing.com - Investing.com South Africa
Nuvalent (NUVL) Receives a New Rating from Truist Financial - The Globe and Mail
Nuvalent’s Cash Cushion Keeps Investors On Board Through Setbacks - Finimize
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders - Finviz
Nuvalent: Deerfield funds sell $70.8m in NUVL stock - Investing.com
Nuvalent closes $500 million public offering of common stock By Investing.com - Investing.com South Africa
Nuvalent Announces Closing of Public Offering of Common Stock an - GuruFocus
Nuvalent Closes Public Offering of Common Shares - marketscreener.com
Nuvalent closes $500 million public offering of common stock - Investing.com
Nuvalent (NASDAQ: NUVL) closes $500M stock offering; 4,950,496 shares sold in public deal - Stock Titan
Nuvalent announces public offering of common stock - MSN
FDA accepts NDA for Nuvalent's zidesamtinib for non-small cell lung cancer - MSN
J.P. Morgan Sticks to Its Buy Rating for Nuvalent (NUVL) - The Globe and Mail
Four companies raise nearly $950M in follow-ons: Public Equity Report - BioCentury
Nuvalent Announces $500M Stock Offering Pricing - The Globe and Mail
Biotech Stock Gets Booted in Latest Fund Update - AOL.com
Will Nuvalent Inc. stock keep outperforming rivalsJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
Why analysts upgrade Nuvalent Inc. stockJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com
Sidley Represents Nuvalent in Pricing of US$500 Million Public Offering - Legal Desire Media and Insights
Jefferies raises Nuvalent stock price target to $164 on promising cancer drug data - Investing.com Nigeria
[8-K] Nuvalent, Inc. Reports Material Event | NUVL SEC FilingForm 8-K - Stock Titan
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC - The Malaysian Reserve
Can Nuvalent Inc. stock surprise with earnings upsideWeekly Trade Report & Safe Capital Growth Plans - newser.com
Will Nuvalent Inc. stock reach Wall Street targetsPortfolio Return Report & Accurate Buy Signal Notifications - newser.com
FDA accepts Nuvalent’s zidesamtinib application for lung cancer treatment By Investing.com - Investing.com Nigeria
Nuvalent Insider Sold Shares Worth $2,065,030, According to a Recent SEC Filing - MarketScreener
Nuvalent Gets FDA Review of Zidesamtinib for ROS1-Positive Lung Cancer - marketscreener.com
FDA accepts Nuvalent’s zidesamtinib application for lung cancer treatment - Investing.com
Nuvalent Executives Sell Over $4.6 Million in Stock - TradingView
Nuvalent Announces FDA Acceptance of New Drug Application for Zi - GuruFocus
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):